Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia
Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, Pijnenburg Y, Keulen MA et al.. Annals of neurology, 2018-11-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants. Methods We conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models. Results Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p Interpretation This study shows that the current PPA classification system helps to predict underlying pathology across different cohorts and clinical settings, and suggests that age and ApoE genotype should be considered when interpreting amyloid-β biomarkers in PPA patients. Ann Neurol 2018;84:737-748.
What this study adds
Evidence grade: High
This is a pooled review of 443 participants. The authors conclude that the current classification "helps to predict underlying pathology" and that age and ApoE genotype "should be considered" when reading amyloid tests in these patients. The study is about diagnosis, not treatment, and the variant alone does not settle any one person's result.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bergeron, D., Gorno-Tempini, M. L., Rabinovici, G. D., Santos-Santos, M. A., Seeley, W., Miller, B. L., et al. (2018). Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of neurology. https://doi.org/10.1002/ana.25333
Vancouver
Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of neurology. 2018. doi:10.1002/ana.25333. PMID: 30255971.
BibTeX
@article{bergeron2018-30255971,
author = {Bergeron, D. and Gorno-Tempini, M. L. and Rabinovici, G. D. and Santos-Santos, M. A. and Seeley, W. and Miller, B. L. and Pijnenburg, Y. and Keulen, M. A. and others},
title = {{Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia}},
journal = {Annals of neurology},
year = {2018},
doi = {10.1002/ana.25333},
pmid = {30255971},
url = {https://doi.org/10.1002/ana.25333}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Amyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p < 0.001).
Why it matters
Pooling individual data from 1,251 people with primary progressive aphasia (a language-led dementia) at 36 centres, this meta-analysis found brain amyloid (an Alzheimer's hallmark, measured by PET, spinal fluid or autopsy) in 86% of the logopenic variant but only 20% of the nonfluent and 16% of the semantic variants. The authors conclude that the current classification "helps to predict underlying pathology" and that age and ApoE genotype "should be considered" when reading amyloid tests in these patients. The study is about diagnosis, not treatment, and the variant alone does not settle any one person's result.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designmeta-analysis
- Participants443
- Evidence strengthHigh
How this study scored 76/100
Published in a leading specialty journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of neurology) |
| Journal's citation record | 3 / 4 | Annals of Neurology: journal h-index 437 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 443 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 5 / 7 | Cited 207 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 20.7 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 4 / 6 | Cited 12.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 12 other studies in this library |
| Still being cited | 3 / 4 | Cited 74 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Rik Ossenkoppele: h-index 84 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 71 institution(s) in 13 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30255971) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 76 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.
Later studies that cite this one
12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.